data.nci.nih.gov/tcga; nationwidechildrens.org_clinical_follow_up_v1.0_kirc.txt and nationwidechildrens.org_clinical_patient_kirc.txt; Version 2.0.25.0May 2015). For n=530 primary ccRCCs and n=208 non-tumor samples, clinical data from TCGA portal as well as expression data and/or methylation data was available. Thereof, expression data was accessible for n=529 primary ccRCCs and n=72 non-tumor samples and methylation data for n=315 primary ccRCCs and n=160 non-tumor samples.
CSS was defined according to Gulati et al (1) , in which always the longest follow-up of all data sources described above was considered. In case of conflicts, CSS was set to NA (not available), therefore leaving 510 and 303 primary ccRCCs for survival analyses of expression and DNA methylation data, respectively. Moreover, consistent CSS, expression, as well as DNA methylation data was available for 302 patients.
CD147 knockdown
For the validation of the CD147 antibody, CD147 was silenced by siRNA mediated knockdown in the renal cell carcinoma cell lines A498, 786-O, Caki1 and Caki2 (CLS, Eppelheim, Germany). A498 and 786-O cells were grown in EMEM or DMEM/Ham's F12, respectively, supplemented with 2 mM L-glutamine and 10% fetal bovine serum.
Caki1 and Caki2 cells were grown in McCoy's 5A with 10% fetal bovine serum and 50 µg/ml gentamicin. CD147 knockdown was performed using a pool of CD147-targeting siRNAs (siGENOME SMARTpool -human BSG, Thermo Scientific, Lafayette, USA). Untreated cells and cells transfected with a pool of non-targeting siRNAs (siGENOME non-targeting siRNA pool #1, Thermo Scientific, Lafayette, USA) were used as controls. Cells were seeded 24h prior to transfection. A final siRNA concentration of 25 nM was transfected using DharmaFECT ® transfection reagent (Thermo Scientific, Lafayette, USA) according to manufacturer's instructions.
Cells were harvested after 72h of incubation. CD147 knockdown was assessed by western blot analysis.
Western Blot
Crude membrane fractions were prepared from CD147-siRNA transfected A498, 
